Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker announced Thursday, days after a private equity takeover bid for the company collapsed.
Debruyne linked his departure to the recent deal.
"After careful reflection on both the process and the outcome of the recent takeover attempt, I have decided to step down to enable the board of Bavarian Nordic to focus on the company’s next phase of development," Debruyne said in a company statement.
A takeover offer from a consortium including Nordic Capital and Permira was withdrawn on Nov. 6 after it failed to secure sufficient shareholder support.
The company said Vice Chair Anne Louise Eberhard has been appointed as the new Chair of the Board.
According to the company, Eberhard said the board's priority is to ensure stability and continuity in governance and leadership.
The new chair also said the board welcomes a "positive dialog with our shareholders about the future composition of the Board" ahead of its 2026 annual general meeting.
More from this issuer
Related coverage
Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker said, days after a takeover bid from a private equity consortium collapsed.
A takeover offer for Danish vaccine maker Bavarian Nordic from a private equity consortium led by Nordic Capital and Permira has been withdrawn after failing to gain sufficient shareholder support.
A private equity consortium's takeover bid for Danish vaccine maker Bavarian Nordic is facing a crucial deadline, complicated by a major new European vaccine contract that could bolster the company's standalone value.
Bavarian Nordic has secured a new long-term contract to supply the European Union with up to 8 million doses of its smallpox and mpox vaccine over the next four years, the company said Friday.